<DOC>
	<DOCNO>NCT00058045</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Stem cell factor may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect cancer therapy . PURPOSE : Phase I trial study effectiveness combine interleukin-2 stem cell factor treat patient AIDS AIDS-related cancer .</brief_summary>
	<brief_title>Interleukin-2 Stem Cell Factor Treating Patients With AIDS AIDS-Related Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity low-dose interleukin-2 stem cell factor patient AIDS AIDS-related malignancy . - Determine immune status patient treat regimen . OUTLINE : This multicenter , dose-escalation study stem cell factor . Patients receive interleukin-2 ( IL-2 ) subcutaneously ( SC ) six day week stem cell factor SC three time week 8 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos stem cell factor maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional cohort 3 patient receive treatment MTD . Patients follow every 2 week 1 month . PROJECTED ACCRUAL : A total 3-18 patient accrue study .</detailed_description>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis HIV1 ELISA , Western blot , polymerase chain reaction , documentation Must 1 follow AIDSdefining illness : Opportunistic infection Opportunistic malignancy ( exclude CNS involvement ) CD4 Tcell count le 200/mm^3 ( currently great 20/mm^3 ) Receiving antiretroviral therapy No concurrent Kaposi 's sarcoma Prior Kaposi 's sarcoma complete response allow PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 80100 % Life expectancy Not specify Hematopoietic Absolute granulocyte count great 1,000/mm^3* Hemoglobin least 10 g/dL* Platelet count great 50,000/mm^3* NOTE : *Transfusions growth factor allow order increase maintain count Hepatic No major hepatic dysfunction evidence encephalopathy , ascites , varix Bilirubin great 2 mg/dL INR great 1.5 Renal Not specify Cardiovascular No prior angioedema No uncontrolled hypertension ( i.e. , diastolic blood pressure great 115 mmHg ) No unstable angina No New York Heart Association class III IV heart disease No congestive heart failure No coronary angioplasty within past 6 month No myocardial infarction within past 6 month No uncontrolled atrial ventricular cardiac arrhythmia Pulmonary No history seasonal recurrent asthma within past 10 year No concurrent asthmatic symptom ( e.g. , wheeze ) relate current respiratory tract infection Immunologic No prior positive allergy test ( skin radioallergosorbent test ) insect venoms No known allergy E. coliderived product No prior anaphylactic event manifest disseminated urticaria , laryngeal edema , and/or bronchospasm Drug allergy manifest solely rash and/or urticaria allow No recurrent urticaria ( isolated episode urticaria allow ) No active uncontrolled infection ( include one current symptom bronchoconstriction ) No fever 38.2Â° C high Fevers due B symptom allow Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior concurrent CNS malignancy No poorly control diabetes No significant nonmalignant disease No malignancy except stable partial response stable complete response ( evidence progressive disease least 8 week therapy malignancy ) PRIOR CONCURRENT THERAPY : Biologic therapy See Hematopoietic Patient Characteristics No prior stem cell factor No concurrent interleukin11 thrombocytopenia Chemotherapy No concurrent chemotherapy malignancy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent enrollment protocol utilizing investigational drug No concurrent beta adrenergic block agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
</DOC>